Companies Market Stem Cell Treatments to Long COVID Patients
Clinics that sell stem cell and exosome treatments have turned their attention to long COVID patients, researchers found. Among 38 businesses selling such treatments for COVID-19, the majority (36) marketed those therapies for long COVID, stated Leigh Turner, PhD, of the University of California Irvine, and colleagues in Stem Cell Reports. “We didn’t think the […]
DOJ Goes After PA for Amniotic Fluid Injections
The Department of Justice (DOJ) has turned its attention to birth tissue products, charging a Texas-based physician assistant with healthcare fraud for allegedly injecting patients with amniotic fluid in a “dubious attempt at pain management,” announced the U.S. Attorney for the Northern District of Texas. Ray Anthony Shoulders, PA, allegedly submitted $788,000 in fraudulent claims […]
Dual-Chamber Leadless Pacemaker Impresses in Safety-and-Performance Study
NEW ORLEANS — A leadless dual-chamber pacemaker with bidirectional wireless communication turned in very promising short-term results in patients with standard indications for dual-chamber pacing, according to the Aveir DR i2i Study. The implantation procedure, consisting of two functioning leadless pacemakers that established implant-to-implant communication, was successful in 98.3% (n=295 of 300) of trial patients, […]
Opinion | What My 10-Year-Old Taught Me About Boundaries
My youngest daughter turned 10 on Saturday. I have been in awe of the privilege, joy, and honor I have been given in raising my beautiful, spirited, brilliant, and incredibly loving kids. One of the most unexpected, amusing, and honestly humbling things I experience with my kids comes from my work as a personal and […]
Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer
NEW YORK — Rucaparib (Rubraca) turned in mixed results for survival outcomes in patients with recurrent ovarian carcinoma, according to an ARIEL3 trial update. There was a benefit for progression-free survival (PFS), as treatment with the PARP inhibitor was tied to longer time-to-second disease progression (PFS2) in patients with BRCA-mutated disease (26.1 months versus 18.4 […]